arXivDaily arXiv每日学术速递 周一至周五更新
arXiv 1607.02283stat.AP
收藏

适应性无缝设计用于建立生物仿制药开发中的药代动力学和疗效等效性

Adaptive seamless design for establishing pharmacokinetics and efficacy equivalence in developing biosimilars

Ryuji Uozumi, Chikuma Hamada

摘要:

最近,许多制药申办者对生物仿制药的开发表现出极大的兴趣,这需要临床试验来证明药代动力学(PK)和临床疗效的等效性。如果有相关PD标志物可用,则药效学(PD)可用于评价疗效。然而,在缺乏这些指标的情况下,有必要设计相关的临床试验,以纳入疗效指标作为主要终点。在这项研究中,我们提出了一种自适应的无缝PK和疗效设计的框架,以纠正错误指定的PK和疗效参数的风险。在此,我们考虑生物类似药的临床开发,包括在需要PK和疗效参数来证明等效性的情况下,在患者而非健康志愿者中进行评价。为了避免与未能确认等效性相关的风险,在拟定方法中考虑在PK部分(有效性部分的早期阶段)中纳入PK等效性的新PK试验,并重新计算有效性等效性的样本量。该建议提供了吸引人的优点,例如较短的时间、额外的成本节省和所需的患者数量较少。

英文摘要:

Recently, numerous pharmaceutical sponsors have expressed a great deal of interest in the development of biosimilars, which requires clinical trials to demonstrate the equivalence of pharmacokinetics (PK) and clinical efficacy. Pharmacodynamics (PD) may be used in evaluating efficacy if there are relevant PD markers available. However, in their absence, it is necessary to design the associated clinical trials to include efficacy measures as the primary endpoint. In this study, we propose an adaptive seamless PK and efficacy design with the frameworks to remedy the risk of misspecification of both PK and efficacy parameters. Here, we consider the clinical development of biosimilars including their evaluation in patients rather than healthy volunteers under a situation where both PK and efficacy parameters are required to demonstrate the equivalence. To avoid the risk associated with the failure to confirm equivalence, incorporating the new PK trial for PK equivalence within the PK portion, which is the early stage for the efficacy part, and sample size re-calculation for the efficacy equivalence are considered in the proposed method. This proposal provides appealing advantages such as a shorter period, additional cost saving, and smaller number of patients required.

机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。

↑